Shots:
- Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors
- The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies
- HX044 is a first-in-class bispecific antibody and next-generation CTLA-4 immunotherapy, being designed for PD-1-resistant tumors like NSCLC, renal cell carcinoma, melanoma & gastrointestinal cancers
Ref: Prnewswire | Image: Hanx Biopharmaceuticals
Related News:- Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
